RESUMEN
BACKGROUND: In the Nordic European Countries, cancer is the leading cause of death. The last decade has brought revolutionizing cancer treatments including immune checkpoint inhibitors (ICIs). Patients on ICIs have a high risk of developing cutaneous immune-related adverse events. Treating these side effects is of high importance to improve patient's quality of life (QoL) and continue the anti-cancer treatment. METHODS: The Nordic European Cutaneous Oncodermatology Management (NECOM) project develops tools to prevent and treat cancer therapy-related cutaneous adverse events (cAEs). The first 2 NECOM papers presented various cAEs and skincare regimens involving hygiene, moisturization, sun protection, and camouflage products for preventing and managing cAEs. The NECOM 3 practical algorithm was on the prevention and treatment of acute radiation dermatitis. This NECOM 4 practical algorithm is intended to prevent and manage cutaneous immunotherapy-related adverse events (cirAEs), improving cancer patients' QoL and outcomes. RESULTS: The NECOM advisors discussed the results of a systematic literature review and obtained consensus on the evidence and expert opinion-based practical algorithm for cirAEs to support all healthcare providers treating cancer patients in the Nordic European Countries. The algorithm starts with a simple skincare regimen of cleansing, moisturizing, and protection, followed by the exclusion of severe cutaneous adverse reactions, and then specific interventions to treat the most common cirAEs (pruritus, maculopapular eruption, eczematous eruption, psoriasis, lichenoid eruption, and bullous eruption). CONCLUSIONS: CirAEs are the most common side effects induced by ICIs and may lead to cancer treatment interruption or even discontinuation. Patient education on the prevention of cirAEs using a skincare regimen and treatment recommendations given in the NECOM 4 algorithm may help prevent and manage cirAEs and improve the QoL and outcome of patients receiving ICIs. J Drugs Dermatol. 2024;23:8(Suppl 2):s4-10.
Asunto(s)
Algoritmos , Inhibidores de Puntos de Control Inmunológico , Neoplasias , Calidad de Vida , Cuidados de la Piel , Humanos , Neoplasias/tratamiento farmacológico , Neoplasias/terapia , Inhibidores de Puntos de Control Inmunológico/efectos adversos , Inhibidores de Puntos de Control Inmunológico/administración & dosificación , Cuidados de la Piel/métodos , Cuidados de la Piel/efectos adversos , Supervivientes de Cáncer , Inmunoterapia/efectos adversos , Inmunoterapia/métodos , Erupciones por Medicamentos/etiología , Erupciones por Medicamentos/diagnóstico , Erupciones por Medicamentos/prevención & control , Erupciones por Medicamentos/terapia , Países Escandinavos y NórdicosRESUMEN
EGFR inhibitors used in the treatment of metastatic wild-RAS colorectal cancer in combination with chemotherapy are associated with dermatologic side events that are low grade in most cases. We report a case of severe cutaneous toxicity secondary to cetuximab associated with bacterial cellulitis. A 57-year-old woman with metastatic adenocarcinoma of the colon, receiving FOLFIRI and Cetuximab as a first-line treatment, presented with a severe erythematous rash and xerosis resistant to local treatment with moisturizing emollients. Few days later, the patient becomes febrile, and the rash becomes more diffuse with a sandpaper appearance on the face, neck, chest, and flexor creases with exfoliation of large areas of skin. A bacterial cellulitis secondary to a dermatologic severe toxicity of Cetuximab was suspected. The patient started on antibiotics and local treatment with good response. This is a life-threatening cutaneous toxicity of cetuximab with secondary bacterial infection. Early recognition of cutaneous side effects of EGFR inhibitors is important to prevent such type of toxicities.
Asunto(s)
Bacteriemia , Neoplasias Colorrectales , Erupciones por Medicamentos , Exantema , Enfermedades de la Piel , Femenino , Humanos , Persona de Mediana Edad , Cetuximab/efectos adversos , Anticuerpos Monoclonales , Celulitis (Flemón)/inducido químicamente , Celulitis (Flemón)/tratamiento farmacológico , Erupciones por Medicamentos/tratamiento farmacológico , Erupciones por Medicamentos/etiología , Erupciones por Medicamentos/prevención & control , Neoplasias Colorrectales/patología , Enfermedades de la Piel/inducido químicamente , Exantema/inducido químicamente , Exantema/tratamiento farmacológico , Receptores ErbB , Bacteriemia/inducido químicamente , Bacteriemia/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Fluorouracilo/uso terapéutico , Leucovorina/uso terapéuticoRESUMEN
Erlotinib is used to treat advanced non-small-cell lung cancer (NSCLC), the common serious adverse events are skin disorders. The dose intensity of erlotinib should be maintained as much as possible by an appropriate control of adverse events in order to maintain its efficacy. Therefore, the management of these adverse events related to skin disorders would enable a continuous erlotinib treatment without interruption and dose reduction. This study assessed the effect of pharmaceutical consultation in outpatients who received erlotinib. Participants included patients with NSCLC who received erlotinib therapy for more than 6 months between December 2007 and March 2019. The participants were divided into two groups: the intervention group that included patients who received pharmaceutical consultation targeting outpatients by a pharmacist and the nonintervention group that included patients who did not. We retrospectively investigated patient characteristics, treatment regimens, and treatment efficacy. We included a total of 33 patients (18 and 15 patients in the nonintervention and intervention groups, respectively) in this study. The intervention group had a significantly higher median relative dose intensity (RDI) of erlotinib than the nonintervention group (p = 0.0437). In addition, the pharmaceutical consultation targeting outpatients was identified as a factor contributing to the maintenance of RDI ≥90% (p = 0.0269). The present study indicated that there was improvement in RDI with pharmaceutical consultation targeting outpatients with advanced NSCLC.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Erupciones por Medicamentos/prevención & control , Clorhidrato de Erlotinib/efectos adversos , Administración del Tratamiento Farmacológico , Derivación y Consulta , Anciano , Atención Ambulatoria/métodos , Atención Ambulatoria/organización & administración , Erupciones por Medicamentos/etiología , Femenino , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Farmacéuticos , Rol Profesional , Estudios RetrospectivosRESUMEN
BACKGROUND: A natural pterostilbene analogue isolated from the herb Sphaerophysa salsula, 3'-hydroxypterostilbene (HPSB), exhibits antiproliferative activity in several cancer cell lines; however, the inhibitory effects of HPSB on skin carcinogenesis remains unclear. PURPOSE: The aim of this study was to evaluate the inhibitory effects of HPSB on two-stage skin carcinogenesis in mice and its potential mechanism. STUDY DESIGN AND METHODS: This study investigated the anti-inflammatory and anti-tumor effects of HPSB in the 12-O-tetradecanoylphorbol-13-acetate (TPA)-stimulated acute skin inflammation and 7,12-dimethylbenz[a]anthracene (DMBA)/TPA-induced two-stage skin carcinogenesis model. In addition, the effects of HPSB on the modulation of the phase I and phase II metabolizing enzymes in the DMBA-induced HaCaT cell model were investigated. RESULTS: The results provide evidence that topical treatment with HPSB significantly inhibits TPA-induced epidermal hyperplasia and leukocyte infiltration through the down-regulation of cyclooxygenase-2 (COX-2), matrix metalloprotein-9 (MMP-9), and ornithine decarboxylase (ODC) protein expression in mouse skin. Furthermore, HPSB suppresses DMBA/TPA-induced skin tumor incidence and multiplicity via the inhibition of proliferating cell nuclear antigen (PCNA), Cyclin B1 and cyclin-dependent kinase 1 (CDK1) expression in the two-stage skin carcinogenesis model. In addition, pretreatment with HPSB markedly reduces DMBA-induced cytochrome P450 1A1 (CYP1A1) and cytochrome P450 1B1 (CYP1B1) gene expression in human keratinocytes; however, HPSB does not significantly affect the gene expression of the phase II enzymes. CONCLUSION: This is the first study to show that topical treatment with HPSB prevents mouse skin tumorigenesis. Overall, our study suggests that natural HPSB may serve as a novel chemopreventive agent capable of preventing carcinogen activation and inflammation-associated tumorigenesis.
Asunto(s)
9,10-Dimetil-1,2-benzantraceno/toxicidad , Anticarcinógenos/farmacología , Neoplasias Cutáneas/prevención & control , Estilbenos/farmacología , Acetato de Tetradecanoilforbol/toxicidad , Administración Tópica , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/farmacología , Anticarcinógenos/administración & dosificación , Carcinógenos/toxicidad , Ciclooxigenasa 2/metabolismo , Erupciones por Medicamentos/etiología , Erupciones por Medicamentos/prevención & control , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Queratinocitos/efectos de los fármacos , Queratinocitos/patología , Ratones Endogámicos ICR , Ornitina Descarboxilasa/metabolismo , Neoplasias Cutáneas/inducido químicamente , Neoplasias Cutáneas/patología , Estilbenos/administración & dosificaciónRESUMEN
Drug reactions resulting from chemotherapy agents are common and frequently affect the skin. Although often benign, a select few of these cutaneous reactions may necessitate immediate changes to the antineoplastic regimens. Given the diversity of chemotherapeutic skin reactions and their complex implications on patient management, an organized conceptual schema is imperative for proper patient care. We evaluate a number of commonly seen chemotherapy-induced skin toxicities organized by pathogenic mechanism and drug class, providing a framework for the identification and categorization of adverse events to prevent unrecognition. Groupings of these reactions include direct cytotoxicity and/or drug accumulation, immunologic hypersensitivity, and aberrant molecular signaling.
Asunto(s)
Antineoplásicos/efectos adversos , Erupciones por Medicamentos/etiología , Erupciones por Medicamentos/terapia , Hipersensibilidad a las Drogas/etiología , Piel/inmunología , Alopecia , Antineoplásicos/inmunología , Antineoplásicos/metabolismo , Erupciones por Medicamentos/clasificación , Erupciones por Medicamentos/prevención & control , Femenino , Síndrome Mano-Pie , Hidradenitis , Humanos , Lupus Eritematoso Cutáneo , Masculino , Piel/efectos de los fármacos , Piel/patologíaRESUMEN
PURPOSE: To describe risk minimization measures (RMMs) implemented in Malaysia for allopurinol-induced severe cutaneous adverse drug reactions (SCARs) and examine their impact using real-world data on allopurinol usage and adverse drug reaction (ADR) reports associated with allopurinol. METHODS: Data on allopurinol ADR reports (2000-2018) were extracted from the Malaysian ADR database. We identified RMMs implemented between 2000 and 2018 from the minutes of relevant meetings and the national pharmacovigilance newsletter. We obtained allopurinol utilization data (2004-2018) from the Pharmaceutical Services Programme. To determine the impact of RMMs on ADR reporting, we considered ADR reports received within 1 year of RMM implementation. We used the Pearson χ2 test to examine the relation between the implementation of RMMs and allopurinol ADR reports. RESULTS: The 16 RMMs for allopurinol-related SCARs implemented in Malaysia involved nine risk communications, four prescriber or patient educational material, and three health system innovations. Allopurinol utilization decreased by 21.5% from 2004 to 2018. ADR reporting rates for all drugs (n = 144 507) and allopurinol (n = 1747) increased. ADR reports involving off-label use decreased by 6% from 2011. SCARs cases remained between 20% and 50%. RMMs implemented showed statistically significant reduction in ADR reports involving off-label use for August 2014 [χ2(1, N = 258) = 5.32, P = .021] and October 2016 [χ2(1, N = 349) = 3.85, P = .0499]. CONCLUSIONS: RMMs to promote the appropriate use of allopurinol and prescriber education have a positive impact. We need further measures to reduce the incidence and severity of allopurinol-induced SCARs, such as patient education and more research into pharmacogenetic screening.
Asunto(s)
Sistemas de Registro de Reacción Adversa a Medicamentos/estadística & datos numéricos , Alopurinol/efectos adversos , Erupciones por Medicamentos/etiología , Supresores de la Gota/efectos adversos , Estudios de Cohortes , Bases de Datos Factuales/estadística & datos numéricos , Erupciones por Medicamentos/patología , Erupciones por Medicamentos/prevención & control , Humanos , Malasia , Farmacovigilancia , Estudios Retrospectivos , Gestión de Riesgos/métodos , Índice de Severidad de la EnfermedadRESUMEN
Importance: Up to 90% of patients treated with an epidermal growth factor receptor inhibitor (EGFRi) experience cutaneous toxic effects that are negatively associated with quality of life and lead to treatment interruptions. The Skin Toxicity Evaluation Protocol With Panitumumab trial found reduced incidence of skin toxicity and quality of life impairment with preemptive use of doxycycline hyclate, topical corticosteroids, moisturizers, and sunscreen, demonstrating the benefit of prophylactic treatment for skin toxicity. Objective: To evaluate the association of a comprehensive skin toxicity program with adherence to prophylaxis guidelines for the prevention of EGFRi-associated cutaneous toxic effects. Design, Setting, and Participants: A retrospective cohort study was conducted of all adult patients receiving at least 1 dose of cetuximab at the Dana-Farber Cancer Institute in the calendar year 2012 (2 years after publication of the Skin Toxicity Evaluation Protocol With Panitumumab) or the calendar year 2017 (2 years after full implementation of the Skin Toxicities from Anticancer Therapies program). Main Outcomes and Measures: Primary outcomes were rate of preemptive rash treatment and selection of preemptive agents. Secondary outcomes were incidence of rash, rates of rescue treatments, rates of cetuximab dose changes or interruptions, and overall survival at 2 years. Results: There were 118 patients (85 men; median age, 62.4 years [range, 23.5-91.7 years]) treated with cetuximab in 2012 and 90 patients (70 men; median age, 62.5 years [range, 30.7-90.5 years]) treated with cetuximab in 2017; 11 patients (9%) in 2012 and 31 patients (34%) in 2017 were treated at Dana-Farber Cancer Institute affiliate sites. At cetuximab treatment initiation, 29 patients (25%) in 2012 and 42 patients (47%) in 2017 were prophylactically treated for skin toxicity (P < .001). From 2012 to 2017, preemptive tetracycline use (13 of 29 [45%] to 30 of 42 [71%]; P = .02) and topical corticosteroid use (2 of 29 [7%] to 24 of 42 [57%]; P < .001) increased and topical antibiotic use (23 of 29 [79%] to 18 of 42 [43%]; P = .002) decreased. There was no significant difference in incidence of rash by prophylaxis status. Patients prescribed prophylactic treatment were 94% less likely to require a first rescue treatment for rash (adjusted odds ratio, 0.06; 95% CI, 0.02-0.16; P < .001), 74% less likely to require a second rescue treatment for rash (adjusted odds ratio, 0.26; 95% CI, 0.08-0.83; P = .02), and 79% less likely to experience a cetuximab dose change or interruption (adjusted odds ratio, 0.21; 95% CI, 0.06-0.81; P = .02) than patients not prescribed prophylactic treatment, adjusting for treatment site and year. Conclusions and Relevance: Dermatologists can add value to oncology care by raising awareness of appropriate treatment options and increasing adherence to evidence-based prophylaxis protocols for EGFRi-associated rash, which is associated with decreased interventions and toxicity-associated chemotherapy interruptions.
Asunto(s)
Instituciones Oncológicas/estadística & datos numéricos , Neoplasias Colorrectales/tratamiento farmacológico , Erupciones por Medicamentos/prevención & control , Adhesión a Directriz/estadística & datos numéricos , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Inhibidores de Proteínas Quinasas/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Instituciones Oncológicas/organización & administración , Instituciones Oncológicas/normas , Cetuximab/administración & dosificación , Cetuximab/efectos adversos , Prestación Integrada de Atención de Salud/organización & administración , Prestación Integrada de Atención de Salud/normas , Prestación Integrada de Atención de Salud/estadística & datos numéricos , Dermatología/organización & administración , Dermatología/normas , Dermatología/estadística & datos numéricos , Erupciones por Medicamentos/etiología , Receptores ErbB/antagonistas & inhibidores , Medicina Basada en la Evidencia/organización & administración , Medicina Basada en la Evidencia/normas , Medicina Basada en la Evidencia/estadística & datos numéricos , Femenino , Adhesión a Directriz/tendencias , Humanos , Masculino , Massachusetts , Oncología Médica/organización & administración , Oncología Médica/normas , Oncología Médica/estadística & datos numéricos , Persona de Mediana Edad , Guías de Práctica Clínica como Asunto , Inhibidores de Proteínas Quinasas/administración & dosificación , Calidad de Vida , Estudios Retrospectivos , Adulto JovenRESUMEN
INTRODUCTION: The use of cytostatic drugs such as Mitomycin C and 5-Fluorouracil is well-known in glaucoma filtering surgery, as well as the management of its complications. However, there is a lack of information regarding the preventive measures to be taken by the professional that handles these types of substances. OBJECTIVE: Raise awareness among professionals of the risks associated with the use of cytostatic drugs without adequate prevention measures. RESULTS: Review of the available literature and legislation on preventive measures in the management of cytostatic drugs in the medical and ophthalmological field. CONCLUSIONS: The prevention and awareness of the risks of the qualified professionals that handle these substances is the most important measure to prevent the possible risks. Coordination is necessary with the Occupational Health teams of the Hospital, as well as the professionals and staff involved in the different phases of the process, from the preparation in Hospital Pharmacy to its elimination.
Asunto(s)
Citostáticos/efectos adversos , Cirugía Filtrante , Glaucoma/cirugía , Sustancias Peligrosas/efectos adversos , Enfermedades Profesionales/inducido químicamente , Salud Laboral , Gestión de Riesgos/métodos , Anomalías Inducidas por Medicamentos/etiología , Anomalías Inducidas por Medicamentos/prevención & control , Accidentes de Trabajo/prevención & control , Conjuntivitis/inducido químicamente , Conjuntivitis/prevención & control , Citostáticos/uso terapéutico , Dermatitis Profesional/etiología , Dermatitis Profesional/prevención & control , Erupciones por Medicamentos/etiología , Erupciones por Medicamentos/prevención & control , Embalaje de Medicamentos , Contaminación de Equipos , Guías como Asunto , Residuos Peligrosos , Cefalea/inducido químicamente , Cefalea/prevención & control , Humanos , Neoplasias/inducido químicamente , Neoplasias/prevención & control , Enfermedades Profesionales/prevención & control , Exposición Profesional , Salud Laboral/legislación & jurisprudencia , Equipo de Protección Personal , Personal de Hospital , Administración de ResiduosRESUMEN
BACKGROUND: Dermatologic adverse events (dAEs) of anticancer therapies may negatively impact dosing and quality of life. While therapy interruption patterns due to dAEs have been studied in hospitalized cancer patients, similar outcomes in outpatient oncodermatology are lacking. OBJECTIVES: To analyse the therapy interruption patterns, clinico-histopathologic characteristics and management outcomes of outpatient dermatology consultations for acute dAEs attributed to the most frequently interrupted class of oncologic agents. METHODS: We performed a retrospective cohort study of all cancer patients who received a same-day outpatient dermatology consultation for acute dAEs at our institution from 1 January to 30 June 2015. Relevant data were abstracted from electronic medical records, including demographics, oncologic history and explicit recommendations by both the referring clinician and consulting dermatologist on anticancer therapy interruption. Consultations with the most frequently interrupted class of oncologic treatment were characterized according to clinico-histopathologic features, dermatologic management and clinical outcomes. RESULTS: There were 426 same-day outpatient dermatology consultations (median age 59, 60% female, 30% breast cancer), of which 295 (69%) had systemic anticancer therapy administered within 30 days prior. There was weak inter-rater agreement between referring clinicians and consulting dermatologists on interruption of anticancer treatment (n = 150, κ = 0.096; 95% CI -0.02 to 0.21). Seventy-three (25%) consultations involved interruption by the referring clinician, most commonly targeted therapy (24, 33%). Maculopapular rash was commonly observed in 23 consultations with 25 dAEs attributed to targeted agents (48%), and topical corticosteroids were most frequently utilized for management (22, 38%). The majority (83%) of consultations with targeted therapy-induced dAEs responded to dermatologic treatment and 84% resumed oncologic therapy, although three (19%) at a reduced dose. Rash recurred only in two instances (13%). CONCLUSIONS: A high frequency of positive outcomes in the management of targeted therapy-induced dAEs by outpatient consulting dermatologists and low recurrence of skin toxicity suggests impactful reductions in interruption of anticancer therapy.
Asunto(s)
Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Erupciones por Medicamentos/prevención & control , Neoplasias/tratamiento farmacológico , Derivación y Consulta , Enfermedades Cutáneas Infecciosas/prevención & control , Adolescente , Corticoesteroides/uso terapéutico , Adulto , Anciano , Alopecia/inducido químicamente , Atención Ambulatoria , Antineoplásicos Inmunológicos/administración & dosificación , Antineoplásicos Inmunológicos/efectos adversos , Dermatología , Erupciones por Medicamentos/tratamiento farmacológico , Erupciones por Medicamentos/patología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Enfermedades de la Uña/inducido químicamente , Inhibidores de Proteínas Quinasas/administración & dosificación , Inhibidores de Proteínas Quinasas/efectos adversos , Estudios Retrospectivos , Enfermedades Cutáneas Infecciosas/inducido químicamenteRESUMEN
Pharmacogenomics (PGx) is increasingly being recognized as a potential tool for improving the efficacy and safety of drug therapy. Therefore, several efforts have been undertaken globally to facilitate the implementation process of PGx into routine clinical practice. Part of these efforts include the formation of PGx working groups working on PGx research, synthesis, and dissemination of PGx data and creation of PGx implementation strategies. In Asia, the Southeast Asian Pharmacogenomics Research Network (SEAPharm) is established to enable and strengthen PGx research among the various PGx communities within but not limited to countries in SEA; with the ultimate goal to support PGx implementation in the region. From the perspective of SEAPharm member countries, there are several key elements essential for PGx implementation at the national level. They include pharmacovigilance database, PGx research, health economics research, dedicated laboratory to support PGx testing for both research and clinical use, structured PGx education, and supportive national health policy. The status of these essential elements is presented here to provide a broad picture of the readiness for PGx implementation among the SEAPharm member countries, and to strengthen the PGx research network and practice in this region.
Asunto(s)
Relaciones Interprofesionales , Farmacogenética/estadística & datos numéricos , Asia , Asia Sudoriental , Enfermedad Hepática Inducida por Sustancias y Drogas/prevención & control , Difusión de Innovaciones , Erupciones por Medicamentos/prevención & control , Humanos , Farmacogenética/economíaRESUMEN
With the development of industry and increase in road traffic, atmospheric pollution has reached unprecedented levels in many regions of the world. Concentrations of pollutants are often far beyond the recommendations of the World Health Organization. Skin, as the first interface between the human body and its environment, is one of the main organs exposed to pollutants and to other environmental factors such as UV irradiation. As much as the effects of pollution and UV irradiation on human skin have been described, the underlying mechanisms remain to be elucidated. This state of the art study aims at exposing the numerous adverse effects of UV and pollution as well as their mode of action on skin. We summarize how these environmental factors negatively impact skin cells: by upregulating xenobiotic metabolism (and bioactivation) and inducing oxidative stress and inflammation, leading to premature aging and a disrupted barrier function. Consequently, we suggest adapted protective measures for the cosmetic industry to support anti-pollution claims.
Asunto(s)
Cosméticos/farmacología , Erupciones por Medicamentos/etiología , Contaminantes Ambientales/toxicidad , Piel/efectos de los fármacos , Antioxidantes/farmacología , Antioxidantes/uso terapéutico , Cosméticos/química , Cosméticos/uso terapéutico , Citocinas/metabolismo , Daño del ADN , Erupciones por Medicamentos/prevención & control , Sinergismo Farmacológico , Emolientes/farmacología , Emolientes/uso terapéutico , Contaminantes Ambientales/farmacocinética , Folículo Piloso/efectos de los fármacos , Folículo Piloso/metabolismo , Humanos , Inactivación Metabólica , Inflamación , Lípidos/fisiología , Estrés Oxidativo , Ozono/toxicidad , Material Particulado/farmacocinética , Material Particulado/toxicidad , Glándulas Sebáceas/efectos de los fármacos , Glándulas Sebáceas/metabolismo , Piel/enzimología , Piel/efectos de la radiación , Absorción Cutánea , Envejecimiento de la Piel , Humo/efectos adversos , Rayos Ultravioleta/efectos adversos , Xenobióticos/farmacocinéticaRESUMEN
PURPOSE: The study aimed to investigate strategies to prevent and treat cetuximab-induced skin reactions and their perceived effectiveness in patients with metastatic colorectal cancer (mCRC) and recurrent/metastatic squamous cell cancer of the head and neck (SCCHN). METHODS: This open-label, prospective observational study was conducted in Switzerland. RESULTS: A total of 125 patients were included (n = 91 mCRC, n = 34 SCCHN; mean age 63.3 years; 73.6% males). The frequency of acneiform rash grade ≥ 2 increased from 12.6% at week 2 to 21.7% at week 16. The proportion of patients who reported no skin reaction decreased from 75.6% at week 2 to 43.3% at week 16. The most frequently used skin products at any time of observation were moisturizing (77.6%), lipid-regenerating (56.8%) or urea-containing products (52%), systemic antibiotics (49.6%), and vitamin K1 cream (43.2%). There was no clear effectiveness pattern for all product classes: in given patients, either the product showed no effect at all or a moderate/strong effect, consistently over time. CONCLUSIONS: A great variety of low-cost general skin care products were commonly used. According to physician's preference, systemic antibiotics and vitamin K1 cream are an appropriate approach to prevent or treat cetuximab-related skin toxicity.
Asunto(s)
Antibacterianos/administración & dosificación , Cetuximab/efectos adversos , Neoplasias Colorrectales/tratamiento farmacológico , Erupciones por Medicamentos , Carcinoma de Células Escamosas de Cabeza y Cuello/tratamiento farmacológico , Vitamina K 1/administración & dosificación , Antineoplásicos Inmunológicos/administración & dosificación , Antineoplásicos Inmunológicos/efectos adversos , Cetuximab/administración & dosificación , Erupciones por Medicamentos/etiología , Erupciones por Medicamentos/prevención & control , Erupciones por Medicamentos/terapia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Crema para la Piel/administración & dosificación , Resultado del Tratamiento , Vitaminas/administración & dosificaciónRESUMEN
BACKGROUND: Approximately 45% of all adverse drug reactions are manifested in the skin. Although most are mild, severe cutaneous adverse reactions (SCARs) are potentially lethal. OBJECTIVE: To review the etiology and clinical manifestations of severe cutaneous adverse reactions (SCARs) and the demographic characteristics of patients with SCARs. METHODS: This study is a retrospective review of electronic medical records for patients who developed drug-induced cutaneous reactions and were treated for initial or ongoing care at a university medical center from June 4, 2008, to August 10, 2018. Search terms included Stevens-Johnson syndrome(SJS) , drug rash with eosinophilia and systemic symptoms(DRESS), acute generalized exanthematous pustulosis(AGEP), toxic epidermal necrolysis (TEN), and TEN/SJS overlap. RESULTS: Of 596 cases of drug-induced rash, 35 cases (5.9%) of SCARs were encountered (male-to-female ratio, 1.06:1.0; mean age, 48.5 years). Of those 35 cases, 32 were in white patients (91.4%). The most common manifestations were DRESS (19 [54.3%]), SJS (8 [22.8%]), AGEP (6 [17.1%]), TEN (1 [2.9%]), and overlap (1 [2.9%]). Multiple causative drugs were implicated in 14 cases, whereas a single drug was responsible in 21 cases. The most common drugs implicated were antibiotics (88.1%). The most common causative antibiotics were cephalosporins (23.7%). Most of the patients with SCARs were given triamcinolone cream and prednisone alone (18 [51.4%]), methylprednisolone alone (1 [2.9%]), methylprednisolone and prednisone combined (4 [11.4%]), methylprednisolone and prednisolone (1 [2.9%]) or prednisone and prednisolone (1 [2.9%]). CONCLUSION: The most common SCARs were, in order, DRESS, SJS, AGEP, TEN, and overlap. The most common causative drugs were, in order, cephalosporins, penicillins, trimethoprim-sulfamethoxazole, and fluoroquinolones.
Asunto(s)
Erupciones por Medicamentos/etiología , Adolescente , Corticoesteroides/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Erupciones por Medicamentos/tratamiento farmacológico , Erupciones por Medicamentos/prevención & control , Femenino , Antagonistas de los Receptores Histamínicos/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Adulto JovenAsunto(s)
Actitud del Personal de Salud , Erupciones por Medicamentos/genética , Erupciones por Medicamentos/prevención & control , Pruebas Genéticas , Conocimientos, Actitudes y Práctica en Salud , Síndrome de Stevens-Johnson/genética , Síndrome de Stevens-Johnson/prevención & control , Academias e Institutos , Alopurinol/efectos adversos , Canadá , Carbamazepina/efectos adversos , Erupciones por Medicamentos/etiología , Humanos , Índice de Severidad de la Enfermedad , Síndrome de Stevens-Johnson/etiologíaAsunto(s)
Erupciones por Medicamentos/epidemiología , Etiquetado de Medicamentos , Errores de Medicación/estadística & datos numéricos , Piel/efectos de los fármacos , Bases de Datos Factuales/estadística & datos numéricos , Erupciones por Medicamentos/etiología , Erupciones por Medicamentos/prevención & control , Francia/epidemiología , Humanos , Errores de Medicación/efectos adversos , Errores de Medicación/prevención & control , Farmacovigilancia , Estudios RetrospectivosRESUMEN
AIM: Human leukocyte antigen (HLA-B*58:01) allele screening before allopurinol administration is recommended to prevent gene-mediated severe cutaneous adverse reactions (SCARs). The objective of the analysis was to examine the clinical utility and effects of HLA-B*58:01 genotyping on patient's outcomes in a practice setting. PATIENTS AND METHODS: The electronic medical records covering diagnosis, laboratory results, and prescription dispensing for patients who were newly treated with allopurinol or tested for HLA-B*58:01 were obtained from a large medical organization in Taiwan between 2010 and 2014. The uptake of HLA-B*58:01 testing, incidence of allopurinol-associated SCAR, and changes in urate-lowering agent utilization were assessed. RESULTS: A total of 17 532 allopurinol new users were identified from 2010 to 2014, and the HLA-B*58:01 test was ordered for 2844 (21.76%) of 13 069 new users when available between 2011 and 2014 in the study. The allopurinol-related SCAR events decreased from 0.21% (22/4460) to 0 (0/2167) after the introduction of HLA-B*58:01 testing, accompanied by a gradual increase from 8% (326/4207) to 31% (674/2167) in genotype testing rate. However, the HLA-B*58:01 testing performed before allopurinol prescription was 60.34%, and ~40% of patients were tested after already taking allopurinol. A shift from allopurinol to other urate-lowering agent regimens appeared among new allopurinol users. CONCLUSION: HLA-B*58:01 test was associated with the prevention of allopurinol-induced SCAR. The clinical utility of genotype testing may not be consistent with recommendations for testing, and treatment alternatives are a competitive intervention associated with effective implications in a real-world setting.
Asunto(s)
Alopurinol/efectos adversos , Erupciones por Medicamentos/epidemiología , Técnicas de Genotipaje/métodos , Antígenos HLA-B/genética , Adulto , Anciano , Pueblo Asiatico/genética , Estudios Transversales , Erupciones por Medicamentos/genética , Erupciones por Medicamentos/prevención & control , Diagnóstico Precoz , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana EdadAsunto(s)
Antiinflamatorios no Esteroideos/efectos adversos , Vesícula/etiología , Erupciones por Medicamentos/etiología , Erupciones por Medicamentos/prevención & control , Ibuprofeno/efectos adversos , Biopsia , Vesícula/complicaciones , Erupciones por Medicamentos/complicaciones , Femenino , Humanos , Persona de Mediana Edad , Pruebas del Parche , Piel/patologíaRESUMEN
EGFR-antibodies are associated with significant skin toxicity, including acneiform rash and folliculitis. It remains impossible to predict the occurrence of severe skin toxicity due to the lack of predictive markers. Here, we present the first genome-wide association study (GWAS) to find single nucleotide polymorphisms (SNPs) associated with EGFR inhibitor-induced skin toxicity using data of the multicentre randomized phase III CAIRO2 trial (clinicaltrials.gov NCT00208546). In this study, advanced or metastatic colorectal cancer patients were treated with capecitabine, oxaliplatin and bevacizumab with or without cetuximab. Germline DNA was available in 282 of the 368 patients in the cetuximab arm. Mild skin toxicity occurred in 195 patients (i.e. CTC grade 1 or 2, respectively 91 and 104 patients) and severe skin toxicity (i.e. grade 3) in 36 patients. Grade 4 skin toxicity did not occur. None of the SNPs reached the formal genome wide threshold for significance of 5x10(-8), though SNPs of at least 8 loci did show moderate association (p-value between 5x10(-7) and 5x10(-5)) with the occurrence of grade 3 (severe) skin toxicity. These SNPs did not overlap with SNPs associated with cetuximab efficacy as found in a previous GWAS in the same CAIRO2 cohort. If formally proven by replication, the SNPs associated with severe EGFR induced skin toxicity may be helpful to predict the occurrence and severity of skin toxicity in patients that will receive cetuximab and allow for adequate information on the risk of skin toxicity and prophylactic measurements.